Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

ngs derived from Anadys' completed strategic restructuring.

Operating expenses were $9.7 million for the third quarter of 2008, compared to $10.0 million for the third quarter of 2007. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $0.7 million and $1.4 million for the third quarter of 2008 and 2007, respectively.

The net loss was $9.3 million for the third quarter of 2008, compared to net income of $12.3 million for the third quarter of 2007. Basic and diluted net loss per common share was $0.32 in the third quarter of 2008, compared to net income per common share of $0.43 in the third quarter of 2007. Non-cash share-based expense resulted in a $0.03 increase in basic and diluted net loss per share for the third quarter of 2008 compared to a $0.05 decrease in basic and diluted net income per share for the third quarter 2007.

During the nine months ended September 30, 2008 the Company had no revenue, compared to $23.9 million for the same period in 2007. The revenue recognized in the first nine months of 2007 was primarily derived from the amortization of an upfront payment and a milestone payment under a prior collaboration and the recognition of the previously deferred revenue upon termination of the collaboration. Operating expenses during the nine months ended September 30, 2008 were $25.2 million compared to $28.1 million for the nine months ended September 30, 2007. The decrease in operating expenses was a result of cost savings derived from Anadys' completed restructuring partially offset by increases in development costs for ANA598 and ANA773. For the nine months ended September 30, 2008, Anadys reported a net loss of $23.9 million, compared to $1.4 million for the same period last year. Basic and diluted net loss per common share was $0.83 for the nine months ended September 30, 2008, compared to $0.05 for the same period in 2007.

Recent Development Program Highlights

-- Phase
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... SAN JOSE, Calif. , Sept. 15, 2014 ... for Proposals (RFP) for flexible, printed product demonstrators ... conducts a two-stage RFP process with pre-proposals due ... in January 2015.  Funds for proposals ultimately selected ... (ARL) and have a significant cost share by ...
(Date:9/15/2014)... carbon nanotubes is neat, but Rice University scientists are making ... new fibers created at Rice line up like a fistful ... Mart and his colleagues. , The tricky bit, according to ... journal ACS Nano , is keeping the densely packed ... Left to their own devices, carbon nanotubes form clumps that ...
(Date:9/15/2014)... 15, 2014 Zymo Research Corp., has announced ... for safe ambient temperature storage and transport of ... infectivity of agents in such samples is completely ... of the viral nucleic acids for subsequent analyses.  ... epidemic in West Africa ...
(Date:9/15/2014)... -- The chemistry, taste, and health effects of tea can ... by the nonprofit American Botanical Council (ABC). Recent research by ... effects on the phytochemical compounds in tea ( Camellia sinensis ... Ahmed in the Yunnan province of ... the future of medicinal botanicals. Dr. Ahmed,s report ...
Breaking Biology Technology:FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated ... biomaterials including bioimplants processed from human amniotic membrane, ... offering to sell common stock and warrants has ... of the offering on October 30, 2010, through ...
... 5, 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ... engaged Congressman Curt Weldon to assist in supporting ... at a press conference in New York City ... Congressman Weldon will source, evaluate, and ...
... NEW YORK, July 4, 2011 Reportlinker.com ... is available in its catalogue: ... 2011-2021 http://www.reportlinker.com/p0567594/Stem-Cell-Technologies-World-Market-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy ... market develop this decade? Our new report ...
Cached Biology Technology:MiMedx Group Completes $5,000,000 Private Placement 2MiMedx Group Completes $5,000,000 Private Placement 3Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America 2Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America 3Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America 4Stem Cell Technologies: World Market Outlook 2011-2021 2Stem Cell Technologies: World Market Outlook 2011-2021 3Stem Cell Technologies: World Market Outlook 2011-2021 4Stem Cell Technologies: World Market Outlook 2011-2021 5Stem Cell Technologies: World Market Outlook 2011-2021 6Stem Cell Technologies: World Market Outlook 2011-2021 7Stem Cell Technologies: World Market Outlook 2011-2021 8Stem Cell Technologies: World Market Outlook 2011-2021 9Stem Cell Technologies: World Market Outlook 2011-2021 10Stem Cell Technologies: World Market Outlook 2011-2021 11Stem Cell Technologies: World Market Outlook 2011-2021 12
(Date:9/15/2014)... fears that reef biodiversity may not provide the level ... , In an international study published today, Professor David ... Reef Studies (Coral CoE) says we need to identify ... , In coral reefs, just as in any modern-day ... safe and functioning. , Professor Bellwood says, in ...
(Date:9/15/2014)... vision document, released today by the National Academy ... goals, objectives, and strategies for the program and ... next five years (2015-2020). In addition, the ... be funded in 2015, will include exploratory grants, ... , The $500 million, 30-year program to be ...
(Date:9/15/2014)... Conditions on Earth for the first 500 million years ... the present day, complete with oceans, continents and active ... geologic eon, called the Hadean, has gained substantial new ... that formed more than 4 billion years ago with ... as a possible geological analog for early Earth. , ...
Breaking Biology News(10 mins):Specialized species critical for reefs 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... at Iowa State University have discovered a previously unknown ... Yanhai Yin, an assistant professor in genetics, development and ... called brassinosteroids. The hormone controls the growth of cells. ... how large the plant grows, says Yin. , "Previously, ...
... the oldest synthetic malaria drug, the methylene blue stain, ... a significant contribution to the long-term eradication called for ... study on 160 children with malaria in Burkina Faso, ... have shown that in combination with newer malaria drugs, ...
... Some researchers hope to turn plants into a renewable, ... have to learn how to convert plant biomass into ... efficiently. In new research, chemists have successfully converted cellulose ... the building block called HMF in one step. ...
Cached Biology News:ISU researcher identifies genetic pathway responsible for much of plant growth 2Old stain in a new combination 2Old stain in a new combination 3Plastic that grows on trees, part two 2
For demonstration of Helicobacter pylori...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
... The MitoPT kit is used in conjunction with ... culture and induce apoptosis according to your existing ... as a negative control). Once you have induced ... solution to each population and incubate the cells ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: